Jorge Aparicio

Summary

Affiliation: Medical Oncology Service
Country: Spain

Publications

  1. ncbi request reprint Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study
    Jorge Aparicio
    Department of Medical Oncology, Hospital Universitario La Fe, Avda Campanar 21, E 46009 Valencia, Spain
    J Clin Oncol 23:8717-23. 2005
  2. ncbi request reprint Treatment of stage I testicular germ-cell tumors
    Jorge Aparicio
    Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain
    Med Oncol 23:305-15. 2006
  3. doi request reprint Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study
    Jorge Aparicio
    Hospital Universitario y Politécnico La Fe, Valencia, Spain
    J Clin Oncol 29:4677-81. 2011
  4. doi request reprint Management options for stage I seminoma
    Jorge Aparicio
    Hospital Universitario La Fe, Avda Campanar 21, E 46009 Valencia, Spain
    Expert Rev Anticancer Ther 10:1077-85. 2010
  5. doi request reprint SEOM clinical guidelines for diagnosis and treatment of testicular seminoma (2010)
    Jorge Aparicio
    Servicio de Oncologia Medica, Hospital Universitario La Fe, Valencia, Spain
    Clin Transl Oncol 13:560-4. 2011
  6. ncbi request reprint FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer
    Jorge Aparicio
    Servicio de Oncologia Medica, Hospital Universitario La Fe, Avda Campanar 21, E 46009 Valencia, Spain
    Clin Colorectal Cancer 5:263-7. 2005
  7. ncbi request reprint First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study
    Jorge Aparicio
    Medical Oncology Department of Hospital Universitario La Fe, ES 46009 Valencia, Spain
    Oncology 68:58-63. 2005
  8. doi request reprint Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study
    Xavier Garcia-Del-Muro
    Genitourinary Tumors and Sarcoma Unit, Department of Medical Oncology, Institut Català d Oncologia L Hospitalet, Barcelona, Spain
    J Clin Oncol 26:5416-21. 2008
  9. ncbi request reprint Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: a phase II multicenter study with 3 years' follow-Up
    Carlos Fernandez-Martos
    Department of Medical Oncology, Fundacion Instituto Valenciano de Oncologia, c o Professor Beltrán Báguena 8 y 19, 46009 Valencia, Spain
    J Clin Oncol 22:3016-22. 2004
  10. ncbi request reprint Long-term results of neoadjuvant chemotherapy and combined chemoradiotherapy before surgery in the management of locally advanced oesophageal cancer: a single-centre experience
    Robert Diaz
    Medical Oncology Unit, University Hospital La Fe, Valencia, Spain
    Clin Transl Oncol 11:835-41. 2009

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study
    Jorge Aparicio
    Department of Medical Oncology, Hospital Universitario La Fe, Avda Campanar 21, E 46009 Valencia, Spain
    J Clin Oncol 23:8717-23. 2005
    ..To assess the efficacy of a risk-adapted treatment policy for patients with stage I seminoma by using universally accepted risk criteria...
  2. ncbi request reprint Treatment of stage I testicular germ-cell tumors
    Jorge Aparicio
    Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain
    Med Oncol 23:305-15. 2006
    ....
  3. doi request reprint Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study
    Jorge Aparicio
    Hospital Universitario y Politécnico La Fe, Valencia, Spain
    J Clin Oncol 29:4677-81. 2011
    ..The aim was to reduce both the risk of relapse and the proportion of patients receiving adjuvant chemotherapy while maintaining a high cure rate...
  4. doi request reprint Management options for stage I seminoma
    Jorge Aparicio
    Hospital Universitario La Fe, Avda Campanar 21, E 46009 Valencia, Spain
    Expert Rev Anticancer Ther 10:1077-85. 2010
    ....
  5. doi request reprint SEOM clinical guidelines for diagnosis and treatment of testicular seminoma (2010)
    Jorge Aparicio
    Servicio de Oncologia Medica, Hospital Universitario La Fe, Valencia, Spain
    Clin Transl Oncol 13:560-4. 2011
    ..Residual lesions must be managed by surveillance if they are smaller than 3 cm, while those larger than 3 cm should be evaluated by means of PET. Surgery is only recommended in PET-positive lesions...
  6. ncbi request reprint FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer
    Jorge Aparicio
    Servicio de Oncologia Medica, Hospital Universitario La Fe, Avda Campanar 21, E 46009 Valencia, Spain
    Clin Colorectal Cancer 5:263-7. 2005
    ..The efficacy and safety of an alternating schedule of continuous-infusion 5-FU with leucovorin (LV) plus oxaliplatin (ie, FOLFOX regimen) or irinotecan (ie, FOLFIRI regimen) was assessed in the first-line setting...
  7. ncbi request reprint First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study
    Jorge Aparicio
    Medical Oncology Department of Hospital Universitario La Fe, ES 46009 Valencia, Spain
    Oncology 68:58-63. 2005
    ..The aim of this multicenter phase II study was to assess its efficacy and toxicity in first-line treatment...
  8. doi request reprint Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study
    Xavier Garcia-Del-Muro
    Genitourinary Tumors and Sarcoma Unit, Department of Medical Oncology, Institut Català d Oncologia L Hospitalet, Barcelona, Spain
    J Clin Oncol 26:5416-21. 2008
    ..To assess the long-term efficacy and toxicity of front-line cisplatin-based chemotherapy in patients with stage IIA or IIB testicular seminoma...
  9. ncbi request reprint Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: a phase II multicenter study with 3 years' follow-Up
    Carlos Fernandez-Martos
    Department of Medical Oncology, Fundacion Instituto Valenciano de Oncologia, c o Professor Beltrán Báguena 8 y 19, 46009 Valencia, Spain
    J Clin Oncol 22:3016-22. 2004
    ..To assess tolerance and efficacy of preoperative treatment with uracil/tegafur and radiotherapy (RT) followed by surgery and postoperative flurouracil (FU)/leucovorin (LV) in patients with rectal cancer...
  10. ncbi request reprint Long-term results of neoadjuvant chemotherapy and combined chemoradiotherapy before surgery in the management of locally advanced oesophageal cancer: a single-centre experience
    Robert Diaz
    Medical Oncology Unit, University Hospital La Fe, Valencia, Spain
    Clin Transl Oncol 11:835-41. 2009
    ..However toxicity is substantial and the improvement in overall survival (OS) with this approach is controversial...
  11. ncbi request reprint Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer
    Jorge Aparicio
    Medical Oncology Department of Hospital Universitario La Fe de Valencia, Valencia, Spain
    Oncology 63:42-7. 2002
    ..Diarrhea is the DLT, but it is not more common or severe than that described with irinotecan alone...
  12. ncbi request reprint Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience
    Roberto Diaz
    Medical Oncology Unit, University Hospital La Fe, Valencia, Spain
    Med Oncol 23:347-57. 2006
    ..Little has been published regarding clinical predictors of severe toxicity in patients with metastatic colorectal cancer (CRC) treated with combination chemotherapy (CT) with oxaliplatin and/or irinotecan...
  13. ncbi request reprint Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy
    Roberto Diaz
    Department of Medical Oncology, Hospital Universitari La Fe, Valencia, Spain
    Clin Colorectal Cancer 5:197-202. 2005
    ..The objective of this study was to analyze prognostic factors for survival and to assess the applicability of Kohne's classification in patients treated with irinotecan- or oxaliplatin-based first-line chemotherapy...
  14. ncbi request reprint Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy
    Ana L Yuste
    Hospital Universitario La Fe, Valencia, Spain
    Clin Colorectal Cancer 2:231-4. 2003
    ..AP levels are significantly related to time to progression. Additional factors influencing survival time are elevated tumor marker levels and the existence of liver metastases...
  15. ncbi request reprint Neoadjuvant cisplatin and etoposide, with or without tamoxifen, prior to radiotherapy in high-grade gliomas: a single-center experience
    Roberto Diaz
    Medical Oncology Unit, University Hospital La Fe, Valencia, Spain
    Anticancer Drugs 16:323-9. 2005
    ..We conclude that neoadjuvant cisplatin and etoposide is a feasible regime, although any real advantage over standard adjuvant CT is dubious. Short-course high-dose tamoxifen should not be used alongside primary CT...
  16. ncbi request reprint Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Tri
    Eduardo Diaz-Rubio
    Department of Medical Oncology, Hospital Clinico Universitario San Carlos, Madrid, Spain
    J Clin Oncol 25:4224-30. 2007
    ....
  17. ncbi request reprint Primary hepatic gastrinoma
    Roberto Diaz
    Medical Oncology Unit, University Hospital La Fe, Valencia, Spain
    Dig Dis Sci 48:1665-7. 2003
  18. doi request reprint Long-term results with oral fluoropyrimidines and oxaliplatin-based preoperative chemoradiotherapy in patients with resectable rectal cancer. A single-institution experience
    Robert Díaz Beveridge
    Medical Oncology Department, University Hospital La Fe, C Bulevar Sur, S N, ES 46026 Valencia, Spain
    Clin Transl Oncol 14:471-80. 2012
    ..Neoadjuvant 5-FU-based chemoradiotherapy in resectable rectal cancer (RC) is a standard of treatment. The use of oral fluoropyrimidines and new agents such as oxaliplatin may improve efficacy and tolerance...
  19. doi request reprint Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer
    Eva Martinez-Balibrea
    Medical Oncology Service, Hospital Universitari Germans Trias i Pujol Institut Català d Oncologia, Badalona, Barcelona, Spain
    Eur J Cancer 44:1229-37. 2008
    ..006) were strong independent prognostic factors. According to this, patients harbouring TS-3'UTR +6bp/+6bp and ERCC1-118C/T or C/C genotypes may better receive capecitabine instead of 5FU in an oxaliplatin-based first-line treatment...
  20. ncbi request reprint The sword of Damocles and the treatment of stage I seminoma
    Tim Oliver
    J Clin Oncol 24:2599-600. 2006
  21. ncbi request reprint A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer
    Juan José Reina
    Hospital Juan Ramon Jimenez, Huelva, Spain
    Cancer Chemother Pharmacol 52:339-45. 2003
    ....
  22. ncbi request reprint Myths and facts on adjuvant carboplatin for stage I seminoma
    Jorge Aparicio
    J Clin Oncol 24:e40. 2006